Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme
Completed
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating patients
who have glioblastoma multiforme.
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Unknown status
Astex Pharmaceuticals
Phase 3
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known whether nitrocamptothecin is more effective
than gemcitabine for pancreatic cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of nitrocamptothecin with
gemcitabine in treating patients who have unresectable locally advanced or metastatic
pancreatic cancer.
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Unknown status
Astex Pharmaceuticals, Inc.
Phase 3
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known whether nitrocamptothecin is more effective
than gemcitabine for pancreatic cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of nitrocamptothecin with
gemcitabine in treating patients who have unresectable locally advanced or metastatic
pancreatic cancer.
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
Unknown status
Astex Pharmaceuticals
Phase 3
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. It is not yet known whether nitrocamptothecin is more effective
than other chemotherapy for cancer of the pancreas.
PURPOSE: Randomized phase III trial to compare the effectiveness of nitrocamptothecin with
that of other chemotherapy in treating patients who have recurrent or refractory cancer of
the pancreas.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
